9I制作厂免费

Abstract:

Cannabinoid receptor type-1 (CB1) was discovered in the 1990s, but the assumptions made by the Pharma industry in the early 2000s were arguably wrong, and led to one of the biggest drug development debacle in Pharma history. A decade later, CB1 biology has greatly evolved and is better understood, thus opening the door to a possible comeback. Dr. George Kunos and his team at the NIH synthesize CB1 blockers with novel characteristics, and teams up with Montral-based Inversago Pharma who will take on the challenge to orchestrate an important paradigm shift. The story of its founders and of the company will be shared.

听

Bio:

Dr. Francois Ravenelle is a 9I制作厂免费 Chemistry graduate obtaining his PhD degree in 2002 under the supervision of the late Professor Bob Marchessault. He is a pharmaceutical development scientist and entrepreneur with more than 20 years of industrial R&D and management experience in drug developmentHe served as Chief Executive Officer and co-founder at Inversago Pharma Inc. (2016-2024), steering the comeback of cannabinoid receptor-1 (CB1) blockers, currently undergoing clinical proof of concept studies. Dr. Ravenelle brough two compounds to the clinic, and launched two Phase 2 with its lead CB1 blocker. He has also worked on a variety of drug products, from small molecules to peptides, and participated in the successful filing and execution of clinical trials while operating in virtual pharma company environments. Before co-founding Inversago, Fran莽ois held several senior level positions with increased responsibilities at Labopharm, Theratechnologies and Verlyx Pharma.